Skip to main content
European Commission logo print header

The Development of Medium- and Large-Scale Sustainable Manufacturing Process Platforms for Clinically Compliant Solid Core Nanopharmaceuticals


A number of nanomedicine formulations have enabled, or been shown to hold considerable potential for enabling more effective and less toxic therapeutic interventions. However, progress to date in translating these initiatives to commercial success has been limited. One of the main reasons for this bottleneck is due to the inability of researchers and stakeholders to manufacture batches of the nanomedicine product at the required scale and according to Good Manufacturing Practice (GMP) requirements. The NANOFACTURING project will focus on
- facilitating access to required infrastructures and expertise
- creating GMP pilot lines for up-scaling manufacturing
- addressing the current developmental and production gaps
- taking nanomaterials already successfully produced at proof-of-concept/milligram levels and facilitating their scale-up to sub-kilogram quantities
- providing large-scale and GMP production for clinical trials and nanomedicine translation.
The NANOFACTURING project, through a consortium of 9 partners, will develop the synthetic processes, process control methods, analytical assays for QA/QC, functional specifications, and best practices, interfacing existing R&D centres of excellence, transfer organisations and private GMP manufacturing facilities (including SMEs) to ensure efficient translation from discovery through to first in man, proof-of-concept studies and beyond to Phase III according to industrial and regulatory standards. Specifically, the NANOFACTURING project aims to create a platform process for early, mid- and large-scale manufacturing of glycan-coated gold nanoparticles (GNPs), a widely researched and developed class of self-forming nanoparticles. The ability to engineer new nanopharmaceuticals based on this patent protected platform technology, developed by Midatech Biogune S.L. (Project Coordinator), will have inherent advantages over existing treatments for multiple therapeutic areas.

Call for proposal


See other projects for this call

Sub call



Net EU contribution
€ 2 516 593,75
Parque tecnologico de bizkaia edificio 800 2a planta
48160 Derio

See on map

Noreste País Vasco Bizkaia
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 0,00

Participants (9)